All News

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Henry and Jade Ranger of The Prescription Shoppe in Williamsburg, Virginia, discussed their practice and what it’s like operating a business together.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the role his company plays in the ongoing issue of rising drug prices.

Check out these featured Drug Topics interviews from September 2024.

The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.

Eroxon topical gel addresses a significant unmet need for men experiencing erectile dysfunction.

“Pharmacies are processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving neffy,” said Eric Karas, CCO of ARS Pharmaceuticals.

Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

In its first move since the July interim report detailing pharmacy benefit manager practices, the FTC is now suing CVS Caremark, Express Scripts, and Optum Rx.

Zevra Therapeutics said it expects the therapy to be commercially available in the United States in 8 to 12 weeks.

Stephanie Sober, MD, MSHP, shares insights into the research that led to Opill’s FDA approval and its implications for women’s access to contraception.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the common misconceptions surrounding PBMs and their role within the supply chain.

Check out important updates from the FDA for the week of September 16.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed ongoing issues within the pharmaceutical supply chain and his organization’s role within it.

Roche announced positive topline results from the phase 3 CENTERSTONE study that evaluated the efficacy of baloxavir marboxil for the reduction of direct flu transmission.

Compounded with lifestyle interventions, researchers compared liraglutide with a placebo to measure its efficacy amongst children under 12 years old.

Following the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.

The Eversense 365 is the world’s first long-term CGM that provides 1 year of use and should be available by the fourth quarter of 2024.

The health care giant’s pharmacy benefit manager subsidiary filed a lawsuit claiming that the FTC’s recent 6(b) report was false and misleading.

The approval was based on data from the phase 3 MANDARA trial, where the therapy met the primary endpoint of proportion of patients in remission at weeks 36 and 48.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.